Pathogenetic mechanisms of atherosclerosis: Effect of lipid lowering on the biology of atherosclerosis

American Journal of Medicine

Volumn 101, Issue 4 A, 1996, Pages 10S-16S

  Ganz, Peter ^a   Creager, Mark A ^a   Fang, James C ^a   McConnell, Michael V ^a   Lee, Richard T ^a   Libby, Peter ^a   Selwyn, Andrew P ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CONFERENCE PAPER; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; DRUG EFFECT; PHYSIOLOGY; REVIEW; STENOSIS, OCCLUSION AND OBSTRUCTION; VASCULAR ENDOTHELIUM; VASODILATATION;

ACETYLCHOLINE; ANTILIPEMIC AGENT;

ACETYLCHOLINE; ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CONSTRICTION, PATHOLOGIC; CORONARY DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; VASODILATION;

EID: 0029661985     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(96)00316-6     Document Type: Conference Paper

References (87)

1. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering therapy in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995;333:1301-1307.
3. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001.
4. Levine GN, Keaney JF Jr, Vita JA. Cholesterol reduction in cardiovascular disease. M Engl J Med. 1995;332:512-521.
5. Wissler RW, Vesselinovitch D. Can atherosclerotic plaques regress? Anatomic and biochemical evidence from nonhuman animals models. Am J Cardiol. 1990;65:33F-40F.
6. Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
7. Watts GF, Lewis B, Brunt JNH, et al. Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St. Thomas' Atherosclerosis Regression Study (STARS). Lancet 1992;339:563-569.
8. Waters D, Higginson L, Gladstone P, et al. Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation. 1994;89:959-968.
9. Blankenhorn DH, Azen SP, Kramsch DM, et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med. 1993;119:969-976.
10. Haskell WL, Alderman EL, Fair JM, et al. Effects of intensive multiple risk factor reduction on coronary atherosclerosis and clinical cardiac events in men and women with coronary artery disease: the Stanford Coronary Risk Intervention Project (SCRIP). Circulation. 1994;89:975-990.
11. Sacks FM, Pasternak RC, Gibson CM, Rosner B, Stone PH. Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolemic patients. Lancet. 1994;344:1182-1186.
12. MAAS Investigators. Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet. 1994;344:633-638.
13. Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation. 1995;91:2528-2540.
14. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC-1): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 1995;26:1133-1139.
15. Rossouw JE. Lipid-lowering interventions in angiographic trials. Am J Cardiol. 1995;76:86C-92C.
16. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med. 1987;316:1371-1375.
17. Stiel GM, Stiel LSG, Schofer J, Donath K, Mathey DG. Impact of compensatory enlargement of atherosclerotic coronary arteries on angiographic assessment of coronary artery disease. Circulation, 1989;80:1603-1609.
18. Zarins CK, Weisenberg E, Kolettis G, et al. Differential enlargement of artery segments in response to enlarging atherosclerotic plaques. J Vase Surg. 1988;7:386-394.
19. Clarkson TB, Prichard RW, Morgan TM, Petrick GS, Klein PS. Remodeling of coronary arteries in human and nonhuman primates. JAMA. 1994;271:289-294.
20. Higano ST, Nishimura RA. Intravascular ultrasonography. Curr Probl Cardiol. 1994;19:1-55.
21. Hermiller JB, Tenaglia AN, Kisslo KB, et al. In vivo validation of compensatory enlargement of atherosclerotic coronary arteries. Am J Cardiol. 1993;71:665-668.
22. Gerber TC, Erbel R, Gorge G, Ge J, Rupprecht HJ, Meyer J. Extent of atherosclerosis and remodeling of the left main coronary artery determined by intravascular ultrasound. Am J Cardiol. 1994;73:666-671.
23. Losordo DW, Rosenfield K, Kaufman J, Pieczek A, Isner JM. Focal compensatory enlargement of human arteries in response to progressive atherosclerosis. In vivo documentation using intravascular ultrasound. Circulation. 1994;89:2570-2577.
24. Furberg CD, Adams HP Jr, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation. 1994;90:1679-1687.
25. Crouse JR Jr, Byington RP, Bond MG, et al. Pravastatin, lipid and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol. 1995;75:455-459.
26. Giroud D, Li JM, Urban P, Meier B, Rutishauer W. Relation of the site of acute MI to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol. 1992;69:729-732.
27. Hackett D, Davies G, Maseri A. Pre-existing coronary stenoses in patients with first MI are not necessarily severe. Eur Heart J. 1988;9:1317-1323.
28. Ambrose JA, Tannenbaum MA, Alexopoulos D, et al. Angiographic progression of coronary artery disease and the development of MI. J Am Coll Cardiol. 1988;12:56-62.
29. Little WC. Constantinescu M, Applegate RJ, et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation. 1988;78:1157-1166.
30. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle content. Br Heart J. 1993;69:377-381.
31. Davies MJ. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation. 1990;82:II-38-II-46.
32. Falk E. Why do plaques rupture? Circulation. 1992;86(suppl III):30-42.
33. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671.
34. Libby P. Molecular bases of the acute coronary syndromes. Circulation. 1995;91:2844-2850.
35. Henney AM, Wakeley PR, Davies MJ, Foster K, Hembry R, Murphy G, Humphries S. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA. 1991;88:8154-8158.
36. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
37. Galis ZS, Muszynski M, Sukhova GK, et al. Cytokine-stimulated human vascular smooth muscle cells synthesize a complement of enzymes required for extracellular matrix digestion. Circ Res. 1994;75:181-189.
38. Galis ZS, Sukhova G, Kranzhofer R, Clark S, Libby P. Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc Natl Acad Sci USA 1995a;92:402-406.
39. Galis ZS, Sukhova GK, Libby P. Microscopic localization of active proteases by in situ zymography: detection of matrix metalloproteinase activity in vascular tissue. FASEB J. 1995;9:974-980.
40. Nikkari ST, O'Brien KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation. 1995;92:1393-1398.
41. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, Fuster V. Human monocyte-denved macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: potential role of matrix-degrading metalloproteinases and implications for plaque rupture. Circulation. 1995;92:1565-1569.
42. Amento EP, Ehsani N, Palmer H, Libby P. Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells. Arterioscler Thromb. 1991;11:1223-1230.
43. Van der Wal AC, Becker AE, Van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44.
44. Fuster V, Badimon JJ. Regression or stabilization of atherosclerosis means regression or stabilization of what we don't see in the arteriogram. Eur Heart J. 1995;16(suppl E):6-12.
45. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA. 1989;86:2839-2843.
46. Fuster V. Elucidation of the role of plaque instability and rupture in acute coronary events. Am J Cardiol. 1995;76:24C-33C.
47. Padgett RC, Heistad DD, Mugge A, Armstrong ML, Piegors DJ, Lopez JAG. Vascular responses to activated leukocytes after regression of atherosclerosis. Circ Res. 1992;70:423-429.
48. Armstrong ML, Warner E, Connor W. Regression of coronary atheromatosis in rhesus monkeys. Circ Res. 1970;27:59-67.
49. Clarkson TB, Bond MG, Bullock BC, Marzetta CA. A study of atherosclerosis regression in Macaca mulatta. Exp Mol Pathol. 1981;34:345-368.
50. Small DM, Bond MG, Waugh D, Prack M, Sawyer JK. Physicochemical and histological changes in the arterial wall of nonhuman primates during progression and regression of atherosclerosis. J Clin Invest. 1984;73:1590-1605.
51. McConnell MV, Ganz P, Lee RT, Selwyn AP, Libby P. Imaging atherosclerosis: lesion vs lumen. In: JHC Reiber and EE van der Wall, eds. Cardiovascular Imaging. The Netherlands: Kluwer Academic Publishers, 1996:93-107.
52. Skinner MP, Yuan C, Mitsumori L, Hayes CE, Raines EW, Nelson JA, Ross R. Serial magnetic resonance imaging of experimental atherosclerosis detects lesion fine structure, progression and complications in vivo. Nature Med. 1995;1:69-73.
53. Summers RM, Hedlund LW, Cofer GP, Gottsman MB, Manibo JF, Johnson GA. MR microscopy of the rat carotid artery after balloon injury by using an implanted imaging coil. Magn Reson Med. 1995;33:785-789.
54. Toussaint JF, Southern JF, Fuster V, Kantor HL. T2-weighted contrast for NMR characterization of human atherosclerosis. Arterioscler Thromb Vasc Biol. 1995;15:1533-1542.
55. Meredith IT, Yeung AC, Weidinger FF, et al. Role of impaired endothelium-dependent vasodilation in the ischemic manifestations of coronary artery disease. Circulation. 1993;87(suppl V):V-56-V-66.
56. Meredith IT, Anderson TJ, Uehata A, Yeung AC, Selwyn AP, Ganz P. The role of the endothelium in ischemic coronary syndromes. Am J Cardiol. 1993;72:27C-32C.
57. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288:373-376.
58. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
59. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
60. Lamas S, Marsden PA, Li GK, Tempst P, Michel T. Endothelial nitric oxide synthase: molecular cloning and characterization of a distinct constitutive enzyme isoform. Proc Natl Acad Sci USA. 1992;89:6348-6352.
61. Myers PR, Minor RL Jr, Guerra R, Bates JN, Harrison DG. The vasorelaxant properties of the endothelium-derived relaxing factor more closely resembles S-nitrosocysteine than nitric oxide. Nature. 1990;345:161-163.
62. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046-1051.
63. Lefroy DC, Crake T, Uren NG, Davies GJ, Maseri A. Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans. Circulation. 1993;88:43-54.
64. Quyyumi AA, Dakak N, Andrews NP, et al. Nitric oxide activity in the human coronary circulation. Impact of risk factors for coronary atherosclerosis. J Clin Invest. 1995;95:1747-1755.
65. Vita JA, Treasure CB, Nabel EG, et al. The coronary vasomotor response to acetylcholine relates to risk factors for coronary artery disease. Circulation. 1990;81:491-497.
66. Egashira K, Inou T, Hirooka Y, et al. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest 1993;91:29-37.
67. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans: progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation. 1991;83:391-401.
68. Dyce MC, Anderson TJ, Yeung AC, et al. Indices of LDL particle size closely relate to endothelial function. Circulation. 1993;88:466.
69. Anderson TJ, Meredith IT, Yeung AC, Charbonneau F, Selwyn AP, Ganz P. Endothelium-dependent coronary vasomotion relates to the susceptibility of LDL to oxidation in humans. Circulation. 1996;93:1647-1650.
70. Zeiher AM, Schachlinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis. Circulation. 1994;89:2525-2532.
71. Kuhn FE, Mohler ER, Satler LF, Reagan K, Lu DY, Rackley CE. Effects of high-density lipoprotein on acetylcholine-induced coronary vasoreactivity. Am J Cardiol. 1991;68:1425-1430.
72. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. J Clin Invest. 1993;91:2546-2551.
73. Leung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemia patients. Lancet. 1993;341:1496-1500.
74. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
75. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995;332:488-493.
76. Gordon JB, Ganz P, Nabel EG, Zebede J, Mudge GH, Alexander RW, Selwyn AP. Atherosclerosis and endothelial function influence the coronary vasomotor response to exercise. J Clin Invest. 1989;83:1946-1952.
77. Gage JE, Hess OM, Murakami T, Ritter M, Grimm J, Krayenbuehl HP. Vasoconstriction of stenotic coronary arteries during dynamic exercise in patients with classic angina pectoris: reversibility by nitroglycerin. Circulation. 1986;73:865-876.
78. Yeung AC, Vekshtein VI, Krantz DS, Vita JA, Ryan TJ Jr, Ganz P, Selwyn AP. The effect of atherosclerosis on the vasomotor response of coronary arteries to mental stress. N Engl J Med. 1989;325:1551-1556.
79. Nabel EG, Ganz P, Gordon JB, Alexander RW, Selwyn AP. Dilation of normal and constriction of atherosclerotic coronary arteries caused by the cold pressor test. Circulation. 1988;77:43-52.
80. Nabel EG, Selwyn AP, Ganz P. Paradoxical narrowing of atherosclerotic coronary arteries induced by increases in heart rate. Circulation. 1990;81:850-859.
81. Nabel EG, Selwyn AP, Ganz P. Large coronary arteries in humans are responsive to changes in blood flow: an endothelium-dependent mechanism that fails in patients with atherosclerosis. J Am Coll Cardiol. 1990;16:349-356.
82. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989;80:458-465.
83. Vita JA, Treasure CB, Yeung AC, et al. Patients with evidence of coronary endothelial dysfunction as assessed by acetylcholine infusion demonstrate marked increase in sensitivity to constrictor effects of catecholamines. Circulation. 1992;85:1390-1397.
84. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol. 1995;26:1615-1622.
85. Quyyumi AA, Dakak N, Andrews NP, Gilligan DM, Panza JA, Cannon RO, III. Contribution of nitric oxide to metabolic coronary vasodilation in the human heart. Circulation. 1995;92:320-326.
86. Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation. 1994;89:2519-2524.
87. Andrews TC, Barry J, Naimi C, Allred E, Ganz P, Selwyn AP. The effect of LDL cholesterol reduction on myocardial ischemia in patients with coronary disease. Circulation (in press).